Humanized mice for the study of infectious diseases

Current Opinion in Immunology

Volumn 25, Issue 4, 2013, Pages 428-435

  Brehm, Michael A ^a   Jouvet, Nathalie ^a   Greiner, Dale L ^a   Shultz, Leonard D ^b  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b JACKSON LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT;

DENGUE; DISEASE MODEL; ENGRAFTMENT; EPSTEIN BARR VIRUS INFECTION; EXPERIMENTAL MOUSE; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMANIZED MOUSE; IMMUNE DEFICIENCY; IMMUNE RESPONSE; INFECTION; MALARIA FALCIPARUM; MOUSE STRAIN; NONHUMAN; REVIEW; TYPHOID FEVER; VIRUS INFECTION;

ANIMALS; COMMUNICABLE DISEASES; DISEASE MODELS, ANIMAL; HUMANS; MICE; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84884145979     PISSN: 09527915     EISSN: 18790372     Source Type: Journal    
DOI: 10.1016/j.coi.2013.05.012     Document Type: Review

References (69)

1. Belser J.A., Szretter K.J., Katz J.M., Tumpey T.M. Use of animal models to understand the pandemic potential of highly pathogenic avian influenza viruses. Adv Virus Res 2009, 73:55-97.
2. Dasgupta G., BenMohamed L. Of mice and not humans: how reliable are animal models for evaluation of herpes CD8(+)-T cell-epitopes-based immunotherapeutic vaccine candidates?. Vaccine 2011, 29:5824-5836.
3. Welsh R.M., Che J.W., Brehm M.A., Selin L.K. Heterologous immunity between viruses. Immunol Rev 2010, 235:244-266.
4. Hatziioannou T., Evans D.T. Animal models for HIV/AIDS research. Nat Rev Microbiol 2012, 10:852-867.
5. Mestas J., Hughes C.C. Of mice and not men: differences between mouse and human immunology. J Immunol 2004, 172:2731-2738.
6. Seok J., Warren H.S., Cuenca A.G., Mindrinos M.N., Baker H.V., Xu W., Richards D.R., Donald-Smith G.P., Gao H., Hennessy L., et al. Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci U S A 2013, 110:3507-3512.
7. Berges B.K., Rowan M.R. The utility of the new generation of humanized mice to study HIV-1 infection: transmission, prevention, pathogenesis, and treatment. Retrovirology 2011, 8:65.
8. Wolfe N.D., Dunavan C.P., Diamond J. Origins of major human infectious diseases. Nature 2007, 447:279-283.
9. Ishikawa F., Yasukawa M., Lyons B., Yoshida S., Miyamoto T., Yoshimoto G., Watanabe T., Akashi K., Shultz L.D., Harada M. Development of functional human blood and immune systems in NOD/SCID/IL2 receptor gamma chain null mice. Blood 2005, 106:1565-1573.
10. null mice engrafted with mobilized human hematopoietic stem cell. J Immunol 2005, 174:6477-6489.
11. Ito M., Hiramatsu H., Kobayashi K., Suzue K., Kawahata M., Hioki K., Ueyama Y., Koyanagi Y., Sugamura K., Tsuji K., et al. NOD/SCID/gamma(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells. Blood 2002, 100:3175-3182.
12. Traggiai E., Chicha L., Mazzucchelli L., Bronz L., Piffaretti J.C., Lanzavecchia A., Manz M.G. Development of a human adaptive immune system in cord blood cell-transplanted mice. Science 2004, 304:104-107.
13. Shultz L.D., Ishikawa F., Greiner D.L. Humanized mice in translational biomedical research. Nat Rev Immunol 2007, 7:118-130.
14. Rongvaux A., Takizawa H., Strowig T., Willinger T., Eynon E.E., Flavell R.A., Manz M.G. Human hemato-lymphoid system mice: current use and future potential for medicine. Annu Rev Immunol 2013.
15. Shultz L.D., Brehm M.A., Garcia-Martinez J.V., Greiner D.L. Humanized mice for immune system investigation: progress, promise and challenges. Nat Rev Immunol 2012, 12:786-798.
16. Barre-Sinoussi F., Chermann J.C., Rey F., Nugeyre M.T., Chamaret S., Gruest J., Dauguet C., Axler-Blin C., Vezinet-Brun F., Rouzioux C., Rozenbaum W., Montagnier L. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983, 220:868-871.
17. Gallo R.C., Salahuddin S.Z., Popovic M., Shearer G.M., Kaplan M., Haynes B.F., Palker T.J., Redfield R., Oleske J., Safai B. Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. Science 1984, 224:500-503.
18. Fultz P.N., Siegel R.L., Brodie A., Mawle A.C., Stricker R.B., Swenson R.B., Anderson D.C., McClure H.M. Prolonged CD4+ lymphocytopenia and thrombocytopenia in a chimpanzee persistently infected with human immunodeficiency virus type 1. J Infect Dis 1991, 163:441-447.
19. Johnson B.K., Stone G.A., Godec M.S., Asher D.M., Gajdusek D.C., Gibbs C.J. Long-term observations of human immunodeficiency virus-infected chimpanzees. AIDS Res Hum Retroviruses 1993, 9:375-378.
20. Denton P.W., Garcia J.V. Humanized mouse models of HIV infection. AIDS Rev 2011, 13:135-148.
21. Akkina R. New generation humanized mice for virus research: comparative aspects and future prospects. Virology 2013, 435:14-28.
22. Stoddart C.A., Maidji E., Galkina S.A., Kosikova G., Rivera J.M., Moreno M.E., Sloan B., Joshi P., Long B.R. Superior human leukocyte reconstitution and susceptibility to vaginal HIV transmission in humanized NOD-scid IL-2Rgamma(-/-) (NSG) BLT mice. Virology 2011, 417:154-160.
23. Denton P.W., Garcia J.V. Mucosal HIV-1 transmission and prevention strategies in BLT humanized mice. Trends Microbiol 2012, 20:268-274.
24. Dudek T.E., No D.C., Seung E., Vrbanac V.D., Fadda L., Bhoumik P., Boutwell C.L., Power K.A., Gladden A.D., Battis L., et al. Rapid evolution of HIV-1 to functional CD8(+) T cell responses in humanized BLT mice. Sci Transl Med 2012, 4:143ra98.
25. Denton P.W., Othieno F., Martinez-Torres F., Zou W., Krisko J.F., Fleming E., Zein S., Powell D.A., Wahl A., Kwak Y.T., et al. One percent tenofovir applied topically to humanized BLT mice and used according to the CAPRISA 004 experimental design demonstrates partial protection from vaginal HIV infection, validating the BLT model for evaluation of new microbicide candidates. J Virol 2011, 85:7582-7593.
26. Denton P.W., Krisko J.F., Powell D.A., Mathias M., Kwak Y.T., Martinez-Torres F., Zou W., Payne D.A., Estes J.D., Garcia J.V. Systemic administration of antiretrovirals prior to exposure prevents rectal and intravenous HIV-1 transmission in humanized BLT mice. PLoS ONE 2010, 5:e8829.
27. Wahl A., Swanson M.D., Nochi T., Olesen R., Denton P.W., Chateau M., Garcia J.V. Human Breast Milk and Antiretrovirals Dramatically Reduce Oral HIV-1 Transmission in BLT Humanized Mice. PLoS Pathog 2012, 8:e1002732.
28. Dash P.K., Gorantla S., Gendelman H.E., Knibbe J., Casale G.P., Makarov E., Epstein A.A., Gelbard H.A., Boska M.D., Poluektova L.Y. Loss of neuronal integrity during progressive HIV-1 infection of humanized mice. J Neurosci 2011, 31:3148-3157.
29. Gorantla S., Makarov E., Finke-Dwyer J., Castanedo A., Holguin A., Gebhart C.L., Gendelman H.E., Poluektova L. Links between progressive HIV-1 infection of humanized mice and viral neuropathogenesis. Am J Pathol 2010, 177:2938-2949.
30. Murooka T.T., Deruaz M., Marangoni F., Vrbanac V.D., Seung E., von Andrian U.H., Tager A.M., Luster A.D., Mempel T.R. HIV-infected T cells are migratory vehicles for viral dissemination. Nature 2012, 490:283-287.
31. White R.E., Ramer P.C., Naresh K.N., Meixlsperger S., Pinaud L., Rooney C., Savoldo B., Coutinho R., Bodor C., Gribben J., et al. EBNA3B-deficient EBV promotes B cell lymphomagenesis in humanized mice and is found in human tumors. J Clin Invest 2012, 122:1487-1502.
32. Sato K., Misawa N., Nie C., Satou Y., Iwakiri D., Matsuoka M., Takahashi R., Kuzushima K., Ito M., Takada K., Koyanagi Y. A novel animal model of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in humanized mice. Blood 2011, 117:5663-5673.
33. Imadome K., Yajima M., Arai A., Nakazawa A., Kawano F., Ichikawa S., Shimizu N., Yamamoto N., Morio T., Ohga S., et al. Novel mouse xenograft models reveal a critical role of CD4+ T cells in the proliferation of EBV-infected T and NK cells. PLoS Pathog 2011, 7:e1002326.
34. Kuwana Y., Takei M., Yajima M., Imadome K., Inomata H., Shiozaki M., Ikumi N., Nozaki T., Shiraiwa H., Kitamura N., et al. Epstein-Barr virus induces erosive arthritis in humanized mice. PLoS ONE 2011, 6:e26630.
35. Strowig T., Gurer C., Ploss A., Liu Y.F., Arrey F., Sashihara J., Koo G., Rice C.M., Young J.W., Chadburn A., et al. Priming of protective T cell responses against virus-induced tumors in mice with human immune system components. J Exp Med 2009, 206:1423-1434.
36. Shultz L.D., Saito Y., Najima Y., Tanaka S., Ochi T., Tomizawa M., Doi T., Sone A., Suzuki N., Fujiwara H., et al. Generation of functional human T-cell subsets with HLA-restricted immune responses in HLA class I expressing NOD/SCID/IL2r gamma(null) humanized mice. Proc Natl Acad Sci U S A 2010, 107:13022-13027.
37. Jaiswal S., Pazoles P., Woda M., Shultz L.D., Greiner D.L., Brehm M.A., Mathew A. Enhanced humoral and HLA-A2-restricted dengue virus-specific T-cell responses in humanized BLT NSG mice. Immunology 2012, 136:334-343.
38. Gubler D.J. Dengue and dengue hemorrhagic fever. Clin Microbiol Rev 1998, 11:480-496.
39. Rothman A.L. Immunity to dengue virus: a tale of original antigenic sin and tropical cytokine storms. Nat Rev Immunol 2011, 11:532-543.
40. Zompi S., Harris E. Animal models of dengue virus infection. Viruses 2012, 4:62-82.
41. Bente D.A., Melkus M.W., Garcia J.V., Rico-Hesse R. Dengue fever in humanized NOD/SCID mice. J Virol 2005, 79:13797-13799.
42. Jaiswal S., Pearson T., Friberg H., Shultz L.D., Greiner D.L., Rothman A.L., Mathew A. Dengue virus infection and virus-specific HLA-A2 restricted immune responses in humanized NOD-scid IL2rgammanull mice. PLoS ONE 2009, 4:e7251.
43. Kuruvilla J.G., Troyer R.M., Devi S., Akkina R. Dengue virus infection and immune response in humanized RAG2(-/-)gamma(c)(-/-) (RAG-hu) mice. Virology 2007, 369:143-152.
44. Mota J., Rico-Hesse R. Humanized mice show clinical signs of dengue fever according to infecting virus genotype. J Virol 2009, 83:8638-8645.
45. Mota J., Rico-Hesse R. Dengue virus tropism in humanized mice recapitulates human dengue fever. PLoS ONE 2011, 6:e20762.
46. Cox J., Mota J., Sukupolvi-Petty S., Diamond M.S., Rico-Hesse R. Mosquito bite delivery of dengue virus enhances immunogenicity and pathogenesis in humanized mice. J Virol 2012, 86:7637-7649.
47. Morin T.J., Broering T.J., Leav B.A., Blair B.M., Rowley K.J., Boucher E.N., Wang Y., Cheslock P.S., Knauber M., Olsen D.B., et al. Human monoclonal antibody HCV1 effectively prevents and treats HCV infection in chimpanzees. PLoS Pathog 2012, 8:e1002895.
48. Billerbeck E., de Jong Y., Dorner M., de la Fuente C., Ploss A. Animal models for hepatitis C. Curr Top Microbiol Immunol 2013, 369:49-86.
49. Brezillon N., Brunelle M.N., Massinet H., Giang E., Lamant C., DaSilva L., Berissi S., Belghiti J., Hannoun L., Puerstinger G., et al. Antiviral activity of Bay 41-4109 on hepatitis B virus in humanized Alb-uPA/SCID mice. PLoS ONE 2011, 6:e25096.
50. Bissig K.D., Wieland S.F., Tran P., Isogawa M., Le T.T., Chisari F.V., Verma I.M. Human liver chimeric mice provide a model for hepatitis B and C virus infection and treatment. J Clin Invest 2010, 120:924-930.
51. Washburn M.L., Bility M.T., Zhang L., Kovalev G.I., Buntzman A., Frelinger J.A., Barry W., Ploss A., Rice C.M., Su L. A humanized mouse model to study hepatitis C virus infection, immune response, and liver disease. Gastroenterology 2011, 140:1334-1344.
52. Mercer D.F., Schiller D.E., Elliott J.F., Douglas D.N., Hao C., Rinfret A., Addison W.R., Fischer K.P., Churchill T.A., Lakey J.R., et al. Hepatitis C virus replication in mice with chimeric human livers. Nat Med 2001, 7:927-933.
53. Brown R.J., Hudson N., Wilson G., Rehman S.U., Jabbari S., Hu K., Tarr A.W., Borrow P., Joyce M., Lewis J., et al. Hepatitis C virus envelope glycoprotein fitness defines virus population composition following transmission to a new host. J Virol 2012, 86:11956-11966.
54. Lutgehetmann M., Bornscheuer T., Volz T., Allweiss L., Bockmann J.H., Pollok J.M., Lohse A.W., Petersen J., Dandri M. Hepatitis B virus limits response of human hepatocytes to interferon-alpha in chimeric mice. Gastroenterology 2011, 140(2083):2074-2083.
55. Parry C.M., Hien T.T., Dougan G., White N.J., Farrar J.J. Typhoid fever. N Engl J Med 2002, 347:1770-1782.
56. Libby S.J., Brehm M.A., Greiner D.L., Shultz L.D., McClelland M., Smith K.D., Cookson B.T., Karlinsey J.E., Kinkel T.L., Porwollik S., et al. Humanized nonobese diabetic-scid IL2rgammanull mice are susceptible to lethal Salmonella Typhi infection. Proc Natl Acad Sci U S A 2010, 107:15589-15594.
57. Song J., Willinger T., Rongvaux A., Eynon E.E., Stevens S., Manz M.G., Flavell R.A., Galan J.E. A mouse model for the human pathogen Salmonella typhi. Cell Host Microbe 2010, 8:369-376.
58. Firoz M.M., Pek E.A., Chenoweth M.J., Ashkar A.A. Humanized mice are susceptible to Salmonella typhi infection. Cell Mol Immunol 2011, 8:83-87.
59. Daubersies P., Thomas A.W., Millet P., Brahimi K., Langermans J.A., Ollomo B., BenMohamed L., Slierendregt B., Eling W., Van B.A., et al. Protection against Plasmodium falciparum malaria in chimpanzees by immunization with the conserved pre-erythrocytic liver-stage antigen 3. Nat Med 2000, 6:1258-1263.
60. Jimenez-Diaz M.B., Mulet T., Viera S., Gomez V., Garuti H., Ibanez J., Alvarez-Doval A., Shultz L.D., Martinez A., Gargallo-Viola D., et al. Improved murine model of malaria using Plasmodium falciparum competent strains and non-myelodepleted NOD-scid IL2Rgammanull mice engrafted with human erythrocytes. Antimicrob Agents Chemother 2009, 53:4533-4536.
61. Vaughan A.M., Mikolajczak S.A., Wilson E.M., Grompe M., Kaushansky A., Camargo N., Bial J., Ploss A., Kappe S.H. Complete Plasmodium falciparum liver-stage development in liver-chimeric mice. J Clin Invest 2012, 122:3618-3628.
62. Morosan S., Hez-Deroubaix S., Lunel F., Renia L., Giannini C., Van Rooijen N., Battaglia S., Blanc C., Eling W., Sauerwein R., et al. Liver-stage development of Plasmodium falciparum, in a humanized mouse model. J Infect Dis 2006, 193:996-1004.
63. Mosier D.E., Gulizia R.J., Baird S.M., Wilson D.B. Transfer of a functional human immune system to mice with severe combined immunodeficiency. Nature 1988, 335:256-259.
64. Mosier D.E., Baird S.M., Kirven M.B. EBV-associated B-cell lymphomas following transfer of human peripheral blood lymphocytes to mice with severe combined immune deficiency. Curr Top Microbiol Immunol 1990, 166:317-323.
65. null mouse model of xenogeneic graft-versus-host-like disease and the role of host MHC. Clin Exp Immunol 2009, 157:104-118.
66. Brehm M.A., Cuthbert A., Yang C., Miller D.M., DiIorio P., Laning J., Burzenski L., Gott B., Foreman O., Kavirayani A., et al. Parameters for establishing humanized mouse models to study human immunity: analysis of human hematopoietic stem cell engraftment in three immunodeficient strains of mice bearing the IL2rgamma(null) mutation. Clin Immunol 2010, 135:84-98.
67. McCune J.M., Namikawa R., Kaneshima H., Shultz L.D., Lieberman M., Weissman I.L. The SCID-hu mouse: murine model for the analysis of human hematolymphoid differentiation and function. Science 1988, 241:1632-1639.
68. Lan P., Tonomura N., Shimizu A., Wang S., Yang Y.G. Reconstitution of a functional human immune system in immunodeficient mice through combined human fetal thymus/liver and CD34+ cell transplantation. Blood 2006, 108:487-492.
69. Melkus M.W., Estes J.D., Padgett-Thomas A., Gatlin J., Denton P.W., Othieno F.A., Wege A.K., Haase A.T., Garcia J.V. Humanized mice mount specific adaptive and innate immune responses to EBV and TSST-1. Nat Med 2006, 12:1316-1322.